From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Shield Therapeutics – tick tock …36 days to tits up alley ( or is it just 21 days?)

By Tom Winnifrith | Friday 25 November 2022


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


On 1 August 2022, having failed to raise $30 million in an equity markets fundraise - as I warred here to hoots of derision from BBMs sitting in their underpants in their parent's basement - , Shield Therapeutics (STX) took out a $10 million loan from 13% shareholder AOP Orphan International AG. Now the clock is ticking on that loan.

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 17:05:33